Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
Newron Pharmaceuticals S.p.A. (0QOI) - Net Assets
Latest net assets as of June 2025: £1.58 Million GBP
Based on the latest financial reports, Newron Pharmaceuticals S.p.A. (0QOI) has net assets worth £1.58 Million GBP as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (£61.39 Million) and total liabilities (£59.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | £1.58 Million |
| % of Total Assets | 2.58% |
| Annual Growth Rate | -12.13% |
| 5-Year Change | -91.55% |
| 10-Year Change | -96.07% |
| Growth Volatility | 174.4 |
Newron Pharmaceuticals S.p.A. - Net Assets Trend (2005–2024)
This chart illustrates how Newron Pharmaceuticals S.p.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Newron Pharmaceuticals S.p.A. (2005–2024)
The table below shows the annual net assets of Newron Pharmaceuticals S.p.A. from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | £1.46 Million | +104.87% |
| 2023-12-31 | £-29.91 Million | -113.17% |
| 2022-12-31 | £-14.03 Million | -551.56% |
| 2021-12-31 | £3.11 Million | -81.98% |
| 2020-12-31 | £17.25 Million | -53.13% |
| 2019-12-31 | £36.80 Million | -32.89% |
| 2018-12-31 | £54.84 Million | -19.03% |
| 2017-12-31 | £67.72 Million | +36.13% |
| 2016-12-31 | £49.75 Million | +34.05% |
| 2015-12-31 | £37.11 Million | +26.83% |
| 2014-12-31 | £29.26 Million | +38.74% |
| 2013-12-31 | £21.09 Million | -23.61% |
| 2012-12-31 | £27.61 Million | +319.26% |
| 2011-12-31 | £6.58 Million | -45.98% |
| 2010-12-31 | £12.19 Million | -58.37% |
| 2009-12-31 | £29.28 Million | -36.08% |
| 2008-12-31 | £45.81 Million | -20.19% |
| 2007-12-31 | £57.40 Million | -15.41% |
| 2006-12-31 | £67.86 Million | +298.70% |
| 2005-12-31 | £17.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Newron Pharmaceuticals S.p.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2616100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | £10.69 Million | 732.85% |
| Common Stock | £3.99 Million | 273.80% |
| Total Equity | £1.46 Million | 100.00% |
Newron Pharmaceuticals S.p.A. Competitors by Market Cap
The table below lists competitors of Newron Pharmaceuticals S.p.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tianjin Tianbao Infrastructure Co Ltd
SHE:000965
|
$295.96 Million |
|
Shenzhen Fluence Technology PLC
SHE:300647
|
$295.97 Million |
|
Guangdong Delian Group Co Ltd
SHE:002666
|
$295.99 Million |
|
RITES Limited
NSE:RITES
|
$295.99 Million |
|
Da-Li Development Co Ltd
TW:6177
|
$295.77 Million |
|
Siam Global House Public Company Limited
BK:GLOBAL
|
$295.75 Million |
|
Calbee Inc
PINK:CLBEY
|
$295.58 Million |
|
BK Technologies Inc
NYSE MKT:BKTI
|
$295.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Newron Pharmaceuticals S.p.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -29,908,000 to 1,458,000, a change of 31,366,000.
- Net income of 15,843,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 12,081,000.
- Other factors increased equity by 3,442,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | £15.84 Million | +1086.63% |
| Other Comprehensive Income | £12.08 Million | +828.6% |
| Other Changes | £3.44 Million | +236.08% |
| Total Change | £- | % |
Book Value vs Market Value Analysis
This analysis compares Newron Pharmaceuticals S.p.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 207.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.70x to 207.27x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | £6.03 | £16.28 | x |
| 2006-12-31 | £17.90 | £16.28 | x |
| 2007-12-31 | £9.84 | £16.28 | x |
| 2008-12-31 | £7.68 | £16.28 | x |
| 2009-12-31 | £4.81 | £16.28 | x |
| 2010-12-31 | £1.84 | £16.28 | x |
| 2011-12-31 | £0.91 | £16.28 | x |
| 2012-12-31 | £3.38 | £16.28 | x |
| 2013-12-31 | £1.83 | £16.28 | x |
| 2014-12-31 | £2.31 | £16.28 | x |
| 2015-12-31 | £2.70 | £16.28 | x |
| 2016-12-31 | £3.39 | £16.28 | x |
| 2017-12-31 | £4.15 | £16.28 | x |
| 2018-12-31 | £3.07 | £16.28 | x |
| 2019-12-31 | £2.06 | £16.28 | x |
| 2020-12-31 | £0.97 | £16.28 | x |
| 2021-12-31 | £0.17 | £16.28 | x |
| 2022-12-31 | £-0.79 | £16.28 | x |
| 2023-12-31 | £-1.68 | £16.28 | x |
| 2024-12-31 | £0.08 | £16.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Newron Pharmaceuticals S.p.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1086.63%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.83%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 43.83x
- Recent ROE (1086.63%) is above the historical average (-14.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -87.66% | 0.00% | 0.00x | 1.38x | £-16.62 Million |
| 2006 | -24.17% | -1377.08% | 0.01x | 1.27x | £-23.19 Million |
| 2007 | -19.32% | -275.57% | 0.06x | 1.23x | £-16.83 Million |
| 2008 | -35.72% | -416.07% | 0.06x | 1.32x | £-20.95 Million |
| 2009 | -80.19% | -923.72% | 0.06x | 1.42x | £-26.41 Million |
| 2010 | -168.53% | -2549.01% | 0.04x | 1.57x | £-21.76 Million |
| 2011 | -97.87% | -2301.79% | 0.02x | 2.06x | £-7.10 Million |
| 2012 | -8.60% | -26.61% | 0.20x | 1.62x | £-5.14 Million |
| 2013 | -33.66% | -200.57% | 0.11x | 1.50x | £-9.21 Million |
| 2014 | -34.50% | -648.36% | 0.04x | 1.27x | £-13.02 Million |
| 2015 | -61.48% | -958.66% | 0.05x | 1.20x | £-26.53 Million |
| 2016 | -30.63% | -226.54% | 0.12x | 1.14x | £-20.21 Million |
| 2017 | -7.80% | -39.34% | 0.18x | 1.08x | £-12.05 Million |
| 2018 | -27.42% | -373.54% | 0.07x | 1.09x | £-20.52 Million |
| 2019 | -54.91% | -287.11% | 0.12x | 1.64x | £-23.89 Million |
| 2020 | -121.76% | -399.35% | 0.10x | 2.97x | £-22.72 Million |
| 2021 | -479.59% | -258.61% | 0.11x | 16.25x | £-15.21 Million |
| 2022 | 0.00% | -287.05% | 0.16x | 0.00x | £-16.09 Million |
| 2023 | 0.00% | -179.13% | 0.35x | 0.00x | £-13.23 Million |
| 2024 | 1086.63% | 30.83% | 0.80x | 43.83x | £15.70 Million |
Industry Comparison
This section compares Newron Pharmaceuticals S.p.A.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Newron Pharmaceuticals S.p.A. (0QOI) | £1.58 Million | -87.66% | 37.81x | $295.80 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |